title: Simplification of the blood stem cell transplantation (BSCT) procedure: large volume apheresis and uncontrolled rate cryopreservation at -80 degrees C.
abstract: Very high-dose chemotherapy with autologous blood stem cell (BSC) rescue becomes more and more widely performed. In order to simplify the technique, a large volume apheresis programme combined with an uncontrolled rate cryopreservation at -80 degrees C was developed. Twenty-six patients suffering from multiple myeloma (n = 8), non-Hodgkin's lymphoma (n = 7), dysgerminoma (n = 4), breast cancer (n = 3), Hodgkin's disease (n = 2), acute lymphoblastic leukaemia (n = 1) and acute myelocytic leukaemia (n = 1) were autografted after a classical high-dose chemotherapy regimen. A single large volume apheresis was sufficient to obtain the threshold value of CD34+ BSC in 24/26 transplantations. The haematological recovery was favourably comparable with the previously published data obtained with controlled rate frozen BSC: median time to granulocytes > 1000/microL and to a self-supporting platelet count > 20,000/microL, respectively, 10.5 and 12 d. The treatment-related mortality was confined to 1/26 BSCT. These results indicate that this easy and cost-saving policy of BSCT is efficacious and safe: sustained long-term haematopoiesis, reduced morbidity and mortality were observed.
authors.affiliation: Clinic of Hematology, Erasme University Hospital Brussels ULB, Belgium.
authors.forename: W W
authors.initials: WW
authors.lastname: Feremans
authors.forename: G
authors.initials: G
authors.lastname: Bastin
authors.forename: F L
authors.initials: FL
authors.lastname: Moine
authors.forename: C
authors.initials: C
authors.lastname: Ravoet
authors.forename: J P
authors.initials: JP
authors.lastname: Delville
authors.forename: O
authors.initials: O
authors.lastname: Pradier
authors.forename: G
authors.initials: G
authors.lastname: Wallef
authors.forename: E
authors.initials: E
authors.lastname: Dupont
authors.forename: P
authors.initials: P
authors.lastname: Capel
authors.forename: M
authors.initials: M
authors.lastname: Lambermont
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001781:Blood Component Removal / Q000379:methods; D001943:Breast Neoplasms / Q000628:therapy; D003131:Combined Modality Therapy; D015925:Cryopreservation / Q000379:methods; D018572:Disease-Free Survival; D004407:Dysgerminoma / Q000628:therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells; D006801:Humans; D007938:Leukemia / Q000628:therapy; D008223:Lymphoma / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy; D009369:Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate; D014182:Transplantation, Autologous
chemical_list: D000970:Antineoplastic Agents